Gapping up
In reaction to earnings/guidance:
- PINS +30.8%, IPHI +26.3%, BCO +18%, TPR +12.6%, USCR +11.3%, SLCA +11.3%, CGNX +9.9% (also increases dividend), EGHT +9%, MDCA +8.5%, HOME +7.9%, ALSN +7.7%, ECHO +7.4%, AGI +7.1%, NDLS +6.6%, PEN +6.6%, ORAN +6.6%, LYG +5.8%, KTB +5.8%, ALGT +5.7%, MDC +5.6%, TAP +5.6%, PPC +5.4%, CTB +5.2%, UMC +5.1% (also settles with DOJ), CPG +5.1%, MLM +5.1%, PWR +5%, CNMD +4.9%, GEO +4.8%, EGOV +4.5%, CARR +4.4%, F +4.3%, SRI +4.2%, CTSH +4.2%, IFRX +4.2%, TPX +4.1%, UCTT +4%, NVCR +4%, GMED +3.8%, MTLS +3.8%, RLGY +3.7%, COOP +3.5%, RGR +3.4%, ALKS +3.4%, BXMT +3.4%, YUMC +3.2%, SCI +3.1%, RDS.A +3.1%, SYNH +3.1%, SHOP +3%, ADS +3%, AMP +2.9%, ALXN +2.9%, FMX +2.8%, TAK +2.8%, TXT +2.8%, ATI +2.8%, BC +2.7%, GPI +2.7%, KHC +2.7%, MRNA +2.7%, SAH +2.6%, TROX +2.5%, AVT +2.4%, URI +2.4%, IDXX +2.4%, NOW +2.3%, UTL +2.3%, SAVE +2.2%, AMT +2.2%, GNCA +2.2%, VC +2.2%, AGEN +2.2%, BOOT +2.1%, LKQ +2.1%, CMCSA +2.1%, CACI +2%, NLY +2%, WDC +2%, XYL +1.9%, CDE +1.8%, VVV +1.8%, BPMC +1.6%, PENN +1.6%, LAWS +1.6%, ISBC +1.5%, CHDN +1.5%, MMSI +1.5%, YUM +1.5%, DRE +1.4%, CFX +1.4%, TXRH +1.3%, GPN +1.3%, IP +1.2%, FORM +1.1%, SNN +1.1%, BAX +1.1%, CNX +1.1%, LORL +1%
M&A news:
- IPHI +27.7% (confirms agreement to be acquire by Marvell (MRVL))
- APEI +1.5% (acquires Rasmussen University)
Other news:
- VSTM +10.4% (reports the Lancet published data demonstrating the potential of VS-6766 as treatment for RAS mutant tumors)
- OSTK +4.6% (tZERO signs agreement with Tynton Capital for digitization services)
- HGEN +4.3% (announces dosing of first patient in NIH ACTIV-5 "Big Effect Trial" evaluating lenzilumab for COVID-19)
- MESO +4.1% (provided an update on the potential pathway to marketing approval for its lead product candidate remestemcel-L)
- SYNH +3.1% (to acquire Synteract; acquires Amulet Capital Partners' Synteract)
- MRNA +2.8% (partners with Takeda (TAK) to supply 50 million doses of mRNA vaccine against COVID-19 (mRNA-1273) to Japan)
- REGN +2.3% (announces trial data for COVID-19 cocktail, REGN-COV2, met the primary and key secondary endpoints)
- OR +2.1% (provides corporate update)
- SUN +1.7% (new CFO)
- SRRK +1.5% (prices offering of 2,948,718 shares of its common stock)
- HTGC +1.3% (approved for third SBIC license)
- AMSF +1% (declares special cash dividend of $3.50/share)
- LLY +1% (announces publication of BLAZE-1 data)
Analyst comments:
- EGHT +9% (upgraded to Buy from Hold at Summit Insights)
- CRTO +4.9% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- CTSH +4.2% (upgraded to Outperform from Market Perform at Cowen)
- BBBY +3.8% (upgraded to Outperform from Market Perform at Telsey Advisory Group)
- FVRR +2.7% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)
- VNDA +2.1% (upgraded to Buy from Neutral at Citigroup)
- CB +2% (upgraded to Neutral from Underperform at BofA Securities)